These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33383444)

  • 1. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.
    Zhang S; Zhao J; Bai X; Handley M; Shan F
    Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
    Carnevalli LS; Ghadially H; Barry ST
    Front Immunol; 2021; 12():633685. PubMed ID: 33953710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-15: targeting CD8+ T cells for immunotherapy.
    Diab A; Cohen AD; Alpdogan O; Perales MA
    Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma.
    Liu S; Yang L; Jia S; Zhao R; Jin Z
    Int Immunopharmacol; 2021 Nov; 100():108161. PubMed ID: 34555643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Basic Immunology for Clinical Investigators.
    Stephen B; Hajjar J
    Adv Exp Med Biol; 2017; 995():1-31. PubMed ID: 28321810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.
    Doedens AL; Rubinstein MP; Gross ET; Best JA; Craig DH; Baker MK; Cole DJ; Bui JD; Goldrath AW
    Cancer Immunol Res; 2016 Sep; 4(9):799-811. PubMed ID: 27485135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 15 as a promising candidate for tumor immunotherapy.
    Jakobisiak M; Golab J; Lasek W
    Cytokine Growth Factor Rev; 2011 Apr; 22(2):99-108. PubMed ID: 21531164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.
    Beyranvand Nejad E; Labrie C; van Elsas MJ; Kleinovink JW; Mittrücker HW; Franken KLMC; Heink S; Korn T; Arens R; van Hall T; van der Burg SH
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.
    Zhou T; Damsky W; Weizman OE; McGeary MK; Hartmann KP; Rosen CE; Fischer S; Jackson R; Flavell RA; Wang J; Sanmamed MF; Bosenberg MW; Ring AM
    Nature; 2020 Jul; 583(7817):609-614. PubMed ID: 32581358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades.
    Li JY; Chen YP; Li YQ; Liu N; Ma J
    Mol Cancer; 2021 Feb; 20(1):27. PubMed ID: 33541368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
    Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-resident memory CD8
    Wang T; Shen Y; Luyten S; Yang Y; Jiang X
    Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
    Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
    Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
    Tang Q; Jiang J; Liu J
    Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of immunotherapy for gastrointestinal stromal tumor.
    Tan Y; Trent JC; Wilky BA; Kerr DA; Rosenberg AE
    Cancer Gene Ther; 2017 Mar; 24(3):130-133. PubMed ID: 28186088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.
    Wilson EB; El-Jawhari JJ; Neilson AL; Hall GD; Melcher AA; Meade JL; Cook GP
    PLoS One; 2011; 6(9):e22842. PubMed ID: 21909397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.
    Dhupkar P; Gordon N
    Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.